Increased fecal serine-protease activity in diarrheic IBS patients: a colonic luminal factor impairing colonic permeability and sensitivity.
INTRODUCTION
The intestinal epithelium is faced with the dual task of providing a barrier while also allowing nutrient and water absorption, therefore its integrity is crucial to maintain physiological function and prevent diseases. Defective epithelial barrier function, which can be measured as increased gut permeability, has been implicated in the pathogenesis of both irritable bowel syndrome (IBS) and inflammatory bowel diseases (IBD).
Irritable bowel syndrome is a gastrointestinal disorder characterized by abdominal pain and altered bowel habit, for which there is no apparent structural basis. The diagnosis of irritable bowel syndrome is symptom-based according to the Rome criteria, since 2006 Rome III being the most recent.
"Red flag" symptoms for organic disorders are ruled out by careful history taking and thorough physical examination. Rome III defines IBS as recurrent abdominal pain or discomfort lasting for at least 3 days per month in the last 3 months, which is associated with 2 or more of the following characteristics: improvement with defecation, onset associated with change in stool frequency or onset associated with change in stool form. Irritable bowel syndrome affects 5-20% of the population worldwide, thus increasing interest has recently been shown towards its poorly understood pathophysiology and to possible therapeutic approaches of the disease. Due to intensive research of recent decades, there has been a paradigm shift in IBS pathophysiology from considering it a purely psychosocial disturbance to finding organic backgrounds of the disease. By now, genetic factors, altered "brain-gut axis" -both in terms of altered sensory afferent function and central processing resulting in visceral hypersensitivity -abnormal serotonerg neurotransmission, altered gut motility, changes in the gut microflora, stress, intestinal hyperpermeability and mucosal immune activation have all been implicated in the pathogenesis of IBS. In a preliminary pilot study, it has been shown that fecal supernatants of diarrhea-predominant IBS (IBS-D) patients have a substantially higher serine protease activity, similar to that of patients with ulcerative colitis (UC), when compared with healthy subjects or other subgroups of IBS patients. Certain serine proteases are signaling molecules that cleave protease-activated receptors (PARs), a family of G-protein coupled receptors with a widespread distribution. Four members of the PAR family have been identified so far in human tissues, of which PAR-2 and 4 are highly expressed on intestinal epithelial cells. The primary activating protease of PAR-2 is trypsin, however, serine proteases of other endogenous and/or bacterial origin are also able to cleave the receptor. Activation of PAR-2 modulates several gastrointestinal functions, such as motility, ionic exchange, paracellular permeability, sensory functions and inflammation. Intracolonic but not intraperitoneal administration of the synthetic selective PAR-2 agonist, SLIGRL (H-serine-leucine-isoleucine-glycine-arginine-leucine-OH), produces delayed visceral hyperalgesia in rats associated with increased paracellular permeability. In the intact epithelium the paracellular space between adjacent cells is sealed by dynamically changing tight junctions at the luminal aspect of the apical junction complex, which forms a selectively permeable barrier and is structurally related to the perijunctional actomyosin ring. The integrity of the epithelial barrier is dependent upon the contraction of this perijunctional actomyosin ring and subsequent physical tension on the tight junction, an event that involves the phosphorylation of myosin light chain (MLC), initiated by MLC kinase (MLCK).
Interestingly, both visceral hypersensitivity and impaired intestinal permeability are commonly observed features of IBS. Gut permeability has been reported to be enhanced in 50% of post-infectious IBS patients, in agreement with the study showing increased small intestinal permeability in both the post-infectious and sporadic forms of IBS, characteristically in the diarrhea-predominant subtype, the same subpopulation where increased serine protease activity has been detected. In accordance, the report on the "Walkerton epidemic" -a waterborne outbreak of acute gastroenteritis in Walkerton, Ontario -proved subtle increase in small intestinal permeability in a large number of patients with IBS, however in vitro studies suggest enhanced permeability in colonic biopsies of IBS patients compared to healthy subjects. Therefore it seems that gut permeability in IBS is altered, though the data on the subgroup of IBS patients affected and the exact localization of the defective barrier are still contradictory. It is also well established that impaired intestinal barrier function could facilitate the passage of luminal antigens and lead to mucosal immune response. Furthermore, there is growing evidence for microinflammation of the intestinal and colonic mucosa to play a role in IBS pathogenesis. Thus identifying the role of defective mucosal barrier in IBS pathomechanism and symptom generation may be an important landmark in better understanding of the disease.
Inflammatory bowel disease is a chronic inflammatory condition of the intestines that is characterized by remission and relapses and distills clinically into one of the two major subtypes of disease: ulcerative colitis and Crohn's disease (CD). Current understanding of the underlying pathomechanisms in IBD is that dysregulated mucosal immune response leads to barrier defect triggered by antigenic components of the normal commensal microbiota that There is strong evidence for barrier dysfunction in IBD: hyperpermeability in non-involved segments of the intestine of CD patients as well as in first degree relatives has been reported and increased permeability have also been associated with an increased risk of relapse. Data are however less abundant on paracellular permeability regarding UC. Increase in gut permeability has previously been reported in clinically active UC, which was also shown to correlate with disease severity. Still, gut permeability has not yet been evaluated in remission of the disease.
AIMS
The studies were conducted (i) to investigate the origin of elevated fecal serine protease activity in IBS-D patients, (ii) to evaluate if this elevated colonic luminal serine protease activity may be sufficient to trigger alterations in colonic permeability and sensitivity in mice, (iii) to examine the possible involvement of PAR-2 activation in this process and (iv) to analyze the underlying molecular mechanisms in the tight junction. We also aimed to (v) evaluate whether the high colonic luminal serine-protease activity in UC may contribute to increased gut permeability and (vi) to examine the possible involvement of cathepsin-G and PAR-4 in this process. Furthermore, we aimed (vii) to measure intestinal and colonic permeability of patients with IBS of the diarrhea and of the constipation-predominant subtype in vivo, (viii) to investigate possible correlation between increased gut permeability and clinical symptoms in IBS-D patients and (ix) to measure gut permeability in patients with ulcerative colitis in remission.
PATIENTS AND METHODS

Patient selection
Fecal serine proteases in IBS and in UC, their role in mediating increased colonic permeability and sensitivity in murine model
Demographic data of the patients enrolled in the study are summarized in Table 1 . Patients fulfilling the Rome II criteria for IBS (patient screening was carried out in [2005] [2006] participated in the study. All participants provided medical history and underwent physical examination. In IBS patients other gastrointestinal disorders were excluded by detailed blood and stool analyses, serological assays for coeliac disease, lactose-hydrogen breath test and colonoscopy. Active UC was assessed clinically and endoscopically. The study protocol was approved by the Ethical Committee of the University of Szeged.
All subjects provided written and informed consent to participate. 
Group Number of patients Age mean (range) Sex ratio (M/F)
In vivo gut permeability in IBS and in inactive ulcerative colitis
Demographic data of the patients enrolled in the study are summarized in 
Methods
Fecal samples
Only feces collected in situ, or collected at home and transported within 1 h after defecation to the First Department of Internal Medicine in Szeged, Hungary, were used. Samples were stored at -80°C until transportation on dry ice to INRA Toulouse, France. Upon arrival, 1g of fecal sample was thawed, dissolved, and homogenised in 7ml of Tris buffer, centrifuged (4500 rpm, 10 min, +4C) and filtered (0.2 µm, Nalgene, (Adventure 16, San Diego, California, USA)). The acquired supernatants were used for measuring total protease activity, serine protease activity, polymorphonuclear neutrophil (PMN) and pancreatic elastase, myeloperoxidase (MPO), calprotectin and human secretory leucocyte protease inhibitor (SLPI) activity.
Measurement of fecal enzymatic activities
To measure total fecal serine protease activity, supernatants of fecal homogenates (25 ml) were incubated with 1 ml of reaction buffer ( Enzymatic activities of the supernatants were normalized to protein content.
To determine whether protease activity was dependent upon serine proteases, Biotechnology, Uden, The Netherlands, respectively). Fecal MPO activity was measured as described earlier. Cat-G activity was measured in fecal supernatants from patients with UC and healthy subjects, using N-succinylAla-Ala-Pro-Phe p Nitroanilide (Sigma) as a substrate. Enzymatic activity was measured at 410 nm for 5 minutes at 37°C.
Animals
Congenic 6-9-week old male C57BL/6J wild type (Janvier, Le Genest St-Isle, France) and PAR-2-deficient mice (The Jackson Laboratory, Bar Harbor, Maine, USA) were used. The genetic status of the PAR-2-deficient mice was confirmed by PCR. Mice were housed in polypropylene cages in a light-and temperature-controlled room (12 h/12 h cycles; 20±2°C), were fed standard pellets (Harlan Teklad, Bicester, Oxon, UK), and water was provided ad libitum. The experimental protocols described in the study were approved by the local Institutional Animal Care and Use Committee.
Visceral sensitivity model
Under xylazine/ketamine anaesthesia (both 1. was also assessed, as well as the effect of a selective cathepsin-G inhibitor (SCGI): UC fecal supernatants were pre-incubated for 30 minutes on ice with the inhibitor (0.2mmol/L) and then the mixture was added to the mucosal side of the colonic strip.
Immunohistochemistry of pMLC and ZO-1
At 1 
2.7.Western blot for pMLC
Colonic mucosa was collected from mice 1h after intracolonic infusion with were assessed by ImageJ 1.37 software (NIH, Bethesda, Maryland, USA).
In vivo permeability measurement with 51 Cr-EDTA
To measure intestinal and colonic permeability after an overnight of fasting participants emptied their bladders and consumed 51 Cr-EDTA (Perkin Elmer Life Sciences, Boston, MA, USA) of 1.8 MBq activity dissolved in 100 ml of water, followed by 200 ml of standard meal (Nutridrink, Nutricia, Budapest, Hungary) containing 300 kcal. Study participants were requested to restrain from drinking for 3 hours and from eating for 5 hours. Gut permeability was evaluated by measuring 24-hour urine excretion of orally administered 51 Cr-EDTA, where time periods were chosen to relate to permeability within the proximal (0-3h) and distal (3-5h) small intestine and the large bowel (5-24h).
Urinary output was recorded for each period and the radioactivity of 1 ml aliquots were counted by a gamma-counter (Packard Cobra, Canberra Packard, UK) in duplicates. Gut permeability was expressed as percentage of urinary excretion of the orally administered dose of 51 Cr-EDTA (%).
Evaluation of symptoms in IBS-D patients
IBS-D patients were asked to fill out a questionnaire, regarding their clinical symptoms at the time of the permeability measurement. Stool frequency (/ week) and consistency (according to the Bristol stool scale), frequency of abdominal pain, distension and bloating (/week), intensity of abdominal pain, distension and bloating and quality of life (visual analogue scale /VAS/; %)
were the symptoms being evaluated and correlated to colonic permeability.
Statistical analysis
All data are presented as means ± SEM. For statistical analysis, Prism 4.0 (GraphPad, San Diego, California, USA) was used. Multiple comparisons for fecal enzymatic activities of different patient groups and integrated optical density values of pMLC western blots were analyzed by repeated measures of one-way analysis of variance (ANOVA), followed by Tukey's posttest or Kruskal-Wallis posttest (for MPO activity). Statistical significance for visceral hypersensitivity results was established by using two-way ANOVA, followed by Bonferroni posttest. In vitro permeability results were analyzed with oneway ANOVA, followed by Tukey posttest or two-tailed unpaired t test.
Multiple comparisons for in vivo permeability of different patient groups were analyzed by repeated measures of one-way ANOVA, followed by Tukey's posttest. Unpaired t-test was used to evaluate colonic permeability data in subgroups of UC patients. Linear regression was applied to establish correlation between clinical symptoms and permeability. Statistical significance was accepted at p <0.05.
RESULTS
Fecal serine protease activity
In healthy subjects the total fecal serine protease activity was 698 U/mg of showed a significant increase in UC (p<0.001 and p<0.05, respectively) and INF patients (p<0.05 and p<0.001, respectively), but we found no increase in any of the IBS subgroups.
Visceral hypersensitivity is triggered by elevated serine protease activity of IBS-D supernatants and is dependent on mucosal PAR-2 expression
Intracolonic infusion of fecal supernatants from IBS-D patients administered prior to colorectal distensions in mice significantly increased the abdominal muscle EMG response (a valid criterion representing nociception) at low distension volumes, namely at 0.02, 0.04 and 0.06 ml, compared with the intensity of muscle contractions in animals treated with fecal supernatants of control subjects (0.02 ml, 30.6 (5.9) mV/s vs 3.5 (1.7) mV/s; 0.04 ml, 73.4 (7.9) mV/s vs 18.9 (7.5) mV/s; 0.06 ml, 107.4 (4.4) mV/s vs 53.2 (14.3) mV/s; p<0.05, p<0.001 and p<0.001, respectively). Conversely, colonic instillation of IBS-C supernatants did not evoke alteration of visceral sensitivity to colorectal distension. Incubation of fecal supernatants from IBS-D patients with serine protease inhibitors prior to colonic infusion, prevented the increased EMG response to low volumes of distension (0.02 ml, 2.8 (1.4)mV/s, 0.04 ml, 49.8 (2.9) mV/s; p<0.01, p<0.05, respectively), while protease inhibitors per se had no effect (data not shown). Furthermore, IBS-D supernatants failed to induce allodynia or visceral hypersensitivity in PAR-2-deficient mice (0.02 ml, 4.6 (3.5) mV/s; 0.04 ml, 41.4 (7.0) mV/s; 0.06 m, 59.4 (14.2) mV/s).
Increase in colonic paracellular permeability (CPP) is evoked by elevated serine protease activity of IBS-D fecal supernatants and is PAR-2 dependent
Administration of fecal supernatants from healthy subjects to the mucosal side of the murine colon mounted in Ussing chambers did not significantly alter 
Increase in colonic paracellular permeability (CPP) is evoked by cathepsin-G of UC fecal supernatants and is PAR-4 mediated
Administration of fecal supernatants from healthy subjects to the mucosal side of murine colon mounted in Ussing chambers did not significantly alter CPP, as compared with saline (1.58 ± 0.29 vs. 2.00 ± 0.28nmol/h/cm 2 , ns). In contrast, addition of fecal supernatants from UC patients significantly increased the FITC-dextran flux compared with supernatants from healthy subjects (3.34 ± 0.47nmol/h/cm 2 ; p<0.05) and saline (p<0.01). 
